



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, 31/415, 31/135	A1	(11) International Publication Number: WO 99/09997 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17564 (22) International Filing Date: 25 August 1998 (25.08.98) (30) Priority Data: US 60/056,970 26 August 1997 (26.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/056,970 (CON) Filed on 26 August 1997 (26.08.97) (71) Applicants (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West Seventh Street, Austin, TX 78701 (US). WAKE FOREST UNIVERSITY [US/US]; Medical Center Boulevard, Winston-Salem, NC 27157-1023 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RAAD, Isam [US/US]; 7615 Del Rey, Houston, TX 77071 (US). SHERETZ, Robert [US/US]; 3417 Jameson Lane, Winston-Salem, NC 27106 (US). HACHEM, Ray [US/US]; 3507 Durness Way, Houston, TX 77025 (US).		(74) Agent: BOWLES, Teresa, J.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: EDTA AND OTHER CHELATORS WITH OR WITHOUT ANTIFUNGAL ANTIMICROBIAL AGENTS FOR THE PREVENTION AND TREATMENT OF FUNGAL INFECTIONS (57) Abstract <p>A pharmaceutical composition comprising at least one antifungal agent and at least one chelator, and a method for administering the pharmaceutical composition to a patient having a fungal infection. Another aspect provides a pharmaceutical composition comprising at least one chelator, at least one antifungal agent and at least one monoclonal antibody, wherein the monoclonal antibody is operatively attached to the chelator, and a method of administering this composition to a patient having a fungal infection.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

EDTA AND OTHER CHELATORS WITH OR WITHOUT ANTIFUNGAL ANTIMICROBIAL AGENTS FOR THE PREVENTION AND TREATMENT OF FUNGAL INFECTIONS

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the treatment of fungal infections in mammals. More particularly, the present invention provides methods of treating fungal infections in mammals using pharmaceutical preparations including chelator(s), antifungal agents, and/or
5 monoclonal antibodies. The invention further provides pharmaceutical compositions useful for treating fungal infections.

2. Description of Related Art

Fungi, particularly species of *Candida*, *Aspergillus*, and *Fusarium* are a major cause of
10 infection-related mortality in patients with leukemia and lymphoma. In addition, fungal infection is a major cause of mortality in patients with congenital and acquired deficiencies of the immune system.

For example, several species of *Aspergillus* are known to cause invasive sinopulmonary
15 infections in seriously immunocompromised patients. Following inhalation of spores, clinical aspergillosis can occur in three major presentations. The first presentation, allergic bronchopulmonary aspergillosis, develops when *Aspergillus* species colonize the bronchial tree and release antigens that cause a hypersensitivity pneumonitis. The second presentation, aspergilloma or "fungus ball," develops in pulmonary cavities, often in concert with other lung
20 diseases such as tuberculosis. The third form, invasive pulmonary or disseminated aspergillosis, is a life threatening infection with a high mortality rate.

The drug of choice in treatment of invasive aspergillosis, as well as in most other systemic mycoses, is Amphotericin B. Amphotericin B is a polyene antibiotic produced from a strain of *Streptomyces nodosus*. It is a lipophilic compound which binds to ergosterols in fungal membranes, resulting in the formation of transmembrane channels which allow the escape of metabolites essential to maintaining the viability of the fungal cell. Mammalian cell membranes also contain sterols, and it is believed that this same mechanism of action is responsible for the damaging effects which Amphotericin B is known to exert on mammalian kidney, hematopoietic and central nervous system tissues.

Amphotericin B is not soluble in aqueous solution, and for this reason it is supplied commercially in the form of a colloidal suspension comprising Amphotericin B, desoxycholate, and buffers suspended in a glucose solution. This suspension is usually administered to the patient intravenously over a period of from two to six hours; faster infusions can result in cardiorespiratory arrest. Other possible untoward effects of administering Amphotericin B include fever, nausea and vomiting, diarrhea, renal dysfunction, anemia, hypotension, headache, vertigo, and loss of hearing. Amphotericin B is also available in the form of a phospholipid complex (ABELCET[®], *e.g.*), which offers the advantage of somewhat reduced toxicity for those patients who do not tolerate free Amphotericin B well, although many of the same untoward side effects may be observed in patients receiving this lipid complex form of the drug.

As a consequence of the potential seriousness of its toxic side effects, there is a clear need for an alternative to treating systemic mycoses solely with Amphotericin B and/or other harsh antifungal agents.

SUMMARY OF THE INVENTION

The present invention provides an effective method of treating a systemic fungal infection comprising the steps of obtaining a therapeutically effective amount of a pharmaceutical composition comprising at least one chelator, at least one antifungal agent and a pharmaceutical excipient, diluent or adjuvant, and administering said pharmaceutical composition to a patient having a fungal infection.

For the purposes of this disclosure, the phrase "therapeutically effective amount" is defined as a dosage sufficient to induce a fungicidal or fungistatic effect upon fungi contacted by the composition. That amount of the pharmaceutical composition which is therapeutically effective will depend upon the ingredients comprising the composition, as well as the treatment goals.

For the purposes of this disclosure, the phrase "a chelator" denotes one or more chelators. As used herein, the term "chelator" is defined as a molecule comprising nonmetal atoms, two or more of which atoms are capable of linking or binding with a metal ion to form a heterocyclic ring including the metal ion.

For the purposes of this disclosure, the phrase "an antifungal agent" denotes one or more antifungal agents. As used herein, the term "antifungal agent" is defined as a compound having either a fungicidal or fungistatic effect upon fungi contacted by the compound.

As used herein, the term "fungicidal" is defined to mean having a destructive killing action upon fungi. As used herein, the term "fungistatic" is defined to mean having an inhibiting action upon the growth of fungi.

As used herein the terms "contact", "contacted", and "contacting", are used to describe the process by which a pharmacological agent, *e.g.*, any of the compositions disclosed in the present invention, comes in direct juxtaposition with the target cell.

Preferable chelators for use in the present invention include, but are not limited to, ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA); the disodium, trisodium, tetrasodium, dipotassium, tripotassium, dilithium and diammonium salts of EDTA; the barium, calcium, cobalt, copper, dysprosium, europium, iron, indium, lanthanum, magnesium, manganese, nickel, samarium, strontium, and zinc chelates of EDTA; trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate; N,N-bis(2-hydroxyethyl)glycine; 1,3-diamino-2-hydroxypropane-N,N,N',N'-tetraacetic acid; 1,3-diaminopropane-N,N,N',N'-tetraacetic acid; ethylenediamine-N,N'-diacetic acid; ethylenediamine-N,N'-dipropionic acid dihydrochloride; ethylenediamine-

N,N'-bis(methylenephosphonic acid) hemihydrate; N-(2-hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid; ethylenediamine-N,N,N',N'-tetrakis(methylenephosphonic acid); O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid; N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid; 1,6-hexamethylenediamine-N,N,N',N'-tetraacetic acid; N-(2-hydroxyethyl)iminodiacetic acid; iminodiacetic acid; 1,2-diaminopropane-N,N,N',N'-tetraacetic acid; nitrilotriacetic acid; nitrilotripropionic acid; the trisodium salt of nitrilotris(methylenephosphoric acid); 7,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo [11,11,11] pentatriacontane hexahydrobromide; and triethylenetetramine - N,N,N',N'',N''',N'''-hexaacetic acid. It is contemplated that any chelator which binds barium, calcium, cerium, cobalt, copper, iron, magnesium, manganese, nickel, strontium, or zinc will be acceptable for use in the present invention.

More preferably, the chelators for use in conjunction with the present invention may include ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA); the disodium, trisodium, tetrasodium, dipotassium, tripotassium, dilithium and diammonium salts of EDTA; 1,3-diamino-2-hydroxypropane-N,N,N',N'-tetraacetic acid; 1,3-diaminopropane-N,N,N',N'-tetraacetic acid; O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid; and 7,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo [11,11,11] pentatriacontane hexahydrobromide.

Most preferably, the chelators for use in the present invention may include ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA); the disodium salt of EDTA; 1,3-diaminopropane-N,N,N',N'-tetraacetic acid; and O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid.

Many antifungal agents are known to those of skill in the art and may be useful in the present invention. For example, antifungal agents contemplated for use in the present invention include, but are not limited to, new third generation triazoles such as UK 109,496 (Voriconazole); SCH 56592; ER30346; UK 9746; UK 9751; T 8581; and Flutrimazole; cell wall active cyclic lipopeptides such as Cilofungin LY121019; LY303366 (Echinocandin); and L-743872 (Pneumocandin); allylamines such as Terbinafine; imidazoles such as Omoconazole, Ketoconazole, Terconazole, Econazole, Itraconazole and Fluconazole; polyenes such as

Amphotericin B, Nystatin, Natamycin, Liposomal Amphotericin B, and Liposomal Nystatin; and other antifungal agents including Griseofulvin; BF-796; MTCH 24; BTG-137586; RMP-7/Amphotericin B; Pradimicins (MNS 18184); Benanomycin; Ambisome; ABLC; ABCD; Nikkomycin Z; and Flucytosine.

5

More preferably, the antifungal agents for use in conjunction with the present invention may include polyenes such as Amphotericin B, Nystatin, Natamycin, Liposomal Amphotericin B, and Liposomal Nystatin; cell wall active cyclic lipopeptides such as Cilofungin LY121019; LY303366 (Echinocandin); and L-743872 (Pneumocandin); and other antifungal agents
10 including Griseofulvin and Flucytosine.

Most preferably, the antifungal agents for use in the present invention may include Amphotericin B, Nystatin, Liposomal Amphotericin B, and Liposomal Nystatin.

15 The present invention also provides an effective method of treating a systemic fungal infection comprising the steps of obtaining a therapeutically effective amount of a pharmaceutical composition comprising at least one chelator operatively attached to a monoclonal antibody, at least one antifungal agent and a pharmaceutical excipient, diluent or adjuvant, and administering said pharmaceutical composition to a patient having a fungal
20 infection. The monoclonal antibody is chosen to bind to a specific fungal antigen, and may be prepared according to any known method. The chelators and antifungal agents may be chosen from those indicated above.

Monoclonal antibodies useful in conjunction with the present invention are those that are
25 specific for a targeted species of fungus. In preferred embodiments, the monoclonal antibodies are operatively attached to chelators. For the purposes of this disclosure, the phrase "a monoclonal antibody" denotes one or more monoclonal antibodies. As used herein, the term "monoclonal antibody" is defined as an antibody derived from a single clone of a B lymphocyte. Furthermore, as used herein, the term "operatively attached" connotes a chemical bond, either
30 covalent or ionic, between the monoclonal antibody and chelator. As used herein, the term "specific" indicates that a chemical site on the monoclonal antibody will recognize and bind with

a complementary chemical site on the surface of the cell of at least the fungal pathogen of interest.

The pharmaceutical compositions of the invention are provided to a patient having a fungal infection in an amount sufficient to exert a fungicidal or fungistatic effect upon fungi contacted by the composition. It will be understood with benefit of this disclosure that such dosages may vary considerably according to the patient, the infection presented by the patient, and the particular active ingredients comprising the pharmaceutical composition.

The antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500, 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

More preferably, the antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

Most preferably, the antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily

understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9 and about 10 mg per kg per day, and including all fractional dosages therebetween.

5

The chelators of the present invention may be administered to a patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as
10 about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500, 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

15

More preferably the chelators of the present invention may be administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the
20 quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

25 Most preferably the chelators of the present invention may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5,
30 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, and about 10 mg per kg per day, and including all fractional dosages therebetween.

The monoclonal antibodies operatively attached to chelators may be administered to a patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500, 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

More preferably, the monoclonal antibodies operatively attached to chelators may be administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

Most preferably, the monoclonal antibodies operatively attached to chelators may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, and about 10, and including all fractional dosages therebetween.

The pharmaceutical compositions of the present invention may be administered by any known route, including parenterally and otherwise. This includes oral, nasal (*via* nasal spray or nasal inhaler), buccal, rectal, vaginal or topical administration. Administration may also be by

orthotopic, intradermal subcutaneous, intramuscular, intraperitoneal or intravenous injection and/or infusion. Such compositions may be administered as pharmaceutically acceptable compositions that include pharmacologically acceptable carriers, buffers or other excipients. The phrase "pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a human. For treatment of conditions of the lungs, the preferred route is aerosol delivery to the lung *via* bronchoalveolar lavage or the like.

When administration of the pharmaceutical compositions of the present invention *via* intravenous injection and/or infusion is the preferred route, the pharmaceutical compositions of the present invention should administered gradually over a period of time ranging from 0.001 h to 100 h. More preferably, when administration of the pharmaceutical compositions of the present invention *via* intravenous injection and/or infusion is the preferred route, the pharmaceutical compositions of the present invention should administered gradually over a period of time ranging from 0.1 h to 50 h. Most preferably, when administration of the pharmaceutical compositions of the present invention *via* intravenous injection and/or infusion is the preferred route, the pharmaceutical compositions of the present invention should administered gradually over a period of time ranging from 1 h to 10 h.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIGS. 1-11 display plots of microbial population vs. time for cultures of species of *Aspergillus*, *Candida* and *Fusarium*. Response of these cultures to treatment with antimicrobials, chelators, and combinations thereof are indicated.

FIG. 1 shows the inhibitory effect of EDTA on *Apergillus flavus in vitro*.

FIG. 2 shows the inhibitory effect of EDTA on *Aspergillus terreus in vitro*.

FIG. 3 shows the inhibitory effect of EDTA on *Fusarium oxysporum* *in vitro*.

FIG. 4 shows the inhibitory effect of EDTA on *Candida krusei* *in vitro*.

FIG. 5 shows the synergistic inhibition of *Aspergillus fumigatus* by Amphotericin B and EDTA (1.0 mg/mL) *in vitro*.

5 **FIG. 6** shows the synergistic inhibition of *Aspergillus fumigatus* by Amphotericin B and EDTA (0.1 mg/mL) *in vitro*.

FIG. 7 shows the synergistic inhibition of *Aspergillus flavus* by Amphotericin B and EDTA (1.0 mg/mL) *in vitro*.

10 **FIG. 8** shows the synergistic inhibition of *Aspergillus flavus* by Amphotericin B and EDTA (0.1 mg/mL) *in vitro*.

FIG. 9 shows the synergistic inhibition of *Fusarium solani* by Amphotericin B and EDTA *in vitro*.

FIG. 10 shows the synergistic inhibition of *Aspergillus fumigatus* by Ambisome and EDTA (0.1 mg/mL) *in vitro*.

15 **FIG. 11** shows the synergistic inhibition of *Fusarium solani* by Ambisome and EDTA *in vitro*.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

20 I. FUNGAL INFECTIONS

Infection is believed to be the cause of death in almost half of all patients who die of lymphoma, and in almost three quarters of patients who die of leukemia. Although bacteria are the causative organisms of many such infections, fungi also play a major role in these infection-related mortalities. As noted in the Background section, species of *Candida*, *Aspergillus*, and
25 *Fusarium* are the major causes of fungal infection-related deaths in patients with leukemia and lymphoma. Additionally, fungal infection is a major cause of mortality in patients with congenital and acquired deficiencies of the immune system.

In their usual role as saprophytes on decaying vegetation, *Aspergillus* organisms are not
30 contagious. Infection arises when spores of these ubiquitous fungi are aerosolized in the abiotic

environment. No underlying predisposition of race, age, or sex leads to the development of *Aspergillus* infection.

Although *Aspergillus* infection can be acquired in the community, the largest threat to the immunocompromised patient is exposure to contaminated air in the hospital environment. Patients who have undergone open heart surgery, who have undergone organ or bone marrow transplantation, or who have prolonged neutropenia after anticancer chemotherapy may acquire life-threatening infection either on the wards where they are housed (domiciliary exposure) or when they are taken to the operating theater, radiology suite, or catheterization laboratory for an essential procedure (nondomiciliary exposure). Construction in the hospital, which results in the liberation of large numbers of spores into the immediate environment, is particularly hazardous for these patients (Rubin, 1994; Wade, 1994). Although there is considerable genetic heterogeneity among *Aspergillus* strains in nature, newly developed molecular typing systems have shown that patients are usually infected with a single strain, a finding that allows the clinician to rapidly assess whether two or more cases are from the same environmental source (Birch *et al.*, 1995).

Several species of *Aspergillus* are known to cause invasive sinopulmonary infections in seriously immunocompromised patients. Following inhalation of spores, clinical aspergillosis can occur in three major presentations. The first presentation, allergic bronchopulmonary aspergillosis, develops when *Aspergillus* species colonize the bronchial tree and release antigens that cause a hypersensitivity pneumonitis. The second presentation, aspergilloma or "fungus ball," develops in pulmonary cavities, often in concert with other lung diseases such as tuberculosis. The third form, invasive pulmonary or disseminated aspergillosis, is a life threatening infection with a very high mortality rate.

The present invention provides pharmaceutical compositions and methods for the prevention and treatment of disseminated fungal infections. It is contemplated that the preparations of the invention will be useful in eliminating or inhibiting all types of fungal infections, providing so-called fungicidal or fungistatic effects. For example, the inventors have discovered that chelators have significant growth inhibitory effect against species of *Aspergillus*

(see data in **FIGS. 1-4**). The inventors have further demonstrated conclusively and unexpectedly that, when combined with antifungal agents, chelators show additive to synergistic inhibitory activity against the growth of fungal pathogens (see data in **FIGS. 5-11**). These discoveries provide the basis for a program of prevention and treatment of systemic fungal infections using any of several embodiments of the inventive pharmaceutical formulations, which may comprise various combinations of chelators, antifungal agents, and any necessary excipients, diluents or adjuvants.

In another aspect, the pharmaceutical formulations provided herein comprise chelators chemically bound, covalently, ionically or otherwise, to monoclonal antibodies which bind to the fungal antigen to be treated. Advantageously, the monoclonal antibodies may serve to deliver the attached chelators directly to their intended fungal targets, where the chelators may then bind trace metals such as iron and calcium which might otherwise serve as fungal virulence factors. The inventors contemplate that this preferred embodiment even more effectively eliminates or inhibits fungal infections by decreasing the tendency of the chelators to bind trace metals with which they may come into contact outside of the immediate vicinity of the infection

II. CHELATORS

A chelate is the type of coordination compound in which a central metal ion is attached by coordinate links to two or more nonmetal atoms in the same molecule. Heterocyclic rings are thus formed during chelation, with the metal atom as part of the ring. The molecule comprising the nonmetal linking atoms is termed a chelator. Chelators are used in various chemical applications, for example as titrating agents or as metal ion scavengers. Chelators can be used to remove ions from participation in biological reactions. For example, the well-known chelator ethylenediamine-N,N,N',N',-tetraacetic acid (EDTA) acts as an anticoagulant because it is capable of scavenging calcium ions from the blood.

It is known that iron and other trace metals are essential in the life cycle of microorganisms such as fungi. Without these trace metals, fungi are unable to grow and reproduce. Although iron is abundant in nature, its availability for microbial assimilation is limited owing to the insolubility of ferric ions at neutral or alkaline pH. As a consequence,

many fungi have evolved their own specialized trace metal-scavenging molecules, called siderophores, which bind with trace metals and make them available for uptake by the fungi. The chelators used in conjunction with the present invention provide an inhibitory effect upon fungal pathogens by competing with the fungal siderophores for any available trace metal ions.

5 In this way, the chelators present in the pharmaceutical preparations of the invention "steal" the metal ions essential for fungal growth, effectively causing the fungus to "starve to death." The added antifungal agents and/or monoclonal antibodies of the preparations of the invention can then come in and attack the weakened fungi, thereby destroying them or inhibiting their growth.

10 The inventors have discovered that the chelators of the present invention have significant growth inhibitory effect against species of *Aspergillus*. Referring to **FIG. 1**, it will be seen that EDTA exerts an inhibitory effect upon *Aspergillus flavus* relative to the control population. This effect is most clearly noticeable beginning 12 h after application of the chelator. Referring to **FIG. 2** and **FIG. 3**, similar inhibitory behavior was noticed in cultures of *Aspergillus terreus* and
15 *Fusarium oxysporum* following application of EDTA. The inhibitory effect of EDTA on *Candida krusei* is noticeable only a few hours after contact of the fungus with the chelator, as shown by **FIG. 4**.

Table 1 provides a representative list of chelators useful in conjunction with the present
20 invention. The list provided in Table 1 is not meant to be exhaustive. Preferred chelators are those which bind trace metal ions with a binding constant ranging from 10^1 to 10^{100} ; more preferred chelators are those which bind trace metal ions with a binding constant ranging from 10^{10} to 10^{80} ; most preferred chelators are those which bind trace metal ions with a binding constant ranging from 10^{15} to 10^{60} . Also, preferred chelators are those which are readily
25 attached to a monoclonal antibody, for example 1,3-diaminopropane-N,N,N',N'-tetraacetic acid (DTPA). Furthermore, preferred chelators are those which have been shown to have an inhibitory effect upon target fungal pathogens, for example the disodium salt of EDTA.

Table 1
CHELATORS

ABBREVIATION	FULL NAME
EDTA free acid	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid
EDTA 2Na	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, disodium salt, dihydrate
EDTA 3Na	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, trisodium salt, trihydrate
EDTA 4Na	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, tetrasodium salt, tetrahydrate
EDTA 2K	Ethylenefismir-N,N,N',N',N',N'-tetraacetic acid, dipotassium salt, dihydrate
EDTA 2Li	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, dilithium salt, monhydrate
EDTA 2NH ₄	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, diammonium salt
EDTA 3K	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, tripotassium salt, dihydrate
Ba(II)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, barium chelate
Ca(II)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, calcium chelate
Ce(III)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, cerium chelate
Co(II)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, cobalt chelate
Cu(II)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, copper chelate
Dy(III)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, dysprosium chelate
Eu(III)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, europium chelate
Fe(III)-EDTA	Ethylenediamine-N,N,N',N',N',N'-tetraacetic acid, iron chelate

Table 1 - Continued

ABBREVIATION	FULL NAME
In(III) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, indium chelate
La(III) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, lanthanum chelate
Mg(II) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, magnesium chelate
Mn(II) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, manganese chelate
Ni(II) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, nickel chelate
Sm(III) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, samarium chelate
Sr(II) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, strontium chelate
Zn(II) -EDTA	Ethylenediamine-N,N,N',N'-tetraacetic acid, zinc chelate
CyDTA	trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid, monohydrate
DHEG	N,N-Bis(2-hydroxyethyl)glycine
DTPA-OH	1,3-Diamino-2-hydroxypropane-N,N,N',N'-tetraacetic acid
DTPA	1,3-Diaminopropane-N,N,N',N'-tetraacetic acid
EDDA	Ethylenediamine-N,N'-diacetic acid
EDDP	Ethylenediamine-N,N'-dipropionic acid dihydrochloride
EDDPO	Ethylenediamine-N,N'-bis(methylenephosphonic acid), hemihydrate
EDTA-OH	N-(2-Hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid

Table 1 - Continued

ABBREVIATION	FULL NAME
EDTPO	Ethylenediamine-N,N,N',N'-tetrakis(methylenephosphonic acid)
EGTA	O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid
HBED	N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid
HDTA	1,6-Hexamethylenediamine-N,N,N',N'-tetraacetic acid
HIDA	N-(2-Hydroxyethyl)iminodiacetic acid
IDA	Iminodiacetic acid
Methyl-EDTA	1,2-Diaminopropane-N,N,N',N'-tetraacetic acid
NTA	Nitrilotriacetic acid
NTP	Nitrilotripropionic acid
NTPO	Nitrilotris(methylenephosphoric acid), trisodium salt
O-Bistren	7,19,30-Trioxa-1,4,10,13,16,22,27,33-octaazabicyclo [11,11,11] pentatriacontane, hexahydrobromide
TTHA	Triethylenetetramine - N,N,N',N'',N''',N''''-hexaacetic acid

III. MONOCLONAL ANTIBODIES

Monoclonal antibodies are antibodies derived from a single clone of B lymphocytes. As such, they are homogenous in structure and antigen specificity, making them useful as vectors for directing radionuclides, drugs, or toxins to tissues of interest such as malignant cells.

5

In one embodiment, the pharmaceutical formulations of the invention may comprise chelators chemically attached to monoclonal antibodies which have been designed to bind to the fungal antigen site of interest. Advantageously, the monoclonal antibodies may serve to deliver the attached chelators directly to their intended fungal targets, where the chelators may then bind
10 trace metals which exist in the vicinity of the fungal cell. By delivering the chelator directly to its intended target, scavenging of any nearby trace metals which might otherwise serve as fungal virulence factors is assured.

Means for preparing and characterizing antibodies are well known in the art (See, *e.g.*,
15 Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference). The methods for generating monoclonal antibodies (MAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogenic composition and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of
20 antisera. Typically the animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

As is well known in the art, a given composition may vary in its immunogenicity. It is
25 often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include
30 glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-diazotized benzidine.

As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant (a
5 non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety
10 of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster injection, may also be given. The process of boosting and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized
15 animal can be bled and the serum isolated and stored, and/or the animal can be used to generate MAbs.

MAbs may be readily prepared through use of well-known techniques, such as those exemplified in U. S. Patent No. 4,196,265, incorporated herein by reference. Typically, this
20 technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified administration of approximately 10^6 *Aspergillus fumigatus* conidia (or other species, such as *Aspergillus flavus*, *Aspergillus terreus*, *Candida krusei*, or *Fusarium solani*, or any other fungal pathogen known to affect humans) in 1.0 mL of sterile NaCl solution with 1.0 mL of Freund's incomplete adjuvant. The immunizing composition is administered in a
25 manner effective to stimulate antibody producing cells. Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep frog cells is also possible. The use of rats may provide certain advantages (Goding, 1986, pp. 60-61), but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions.

Following immunization, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible. Often, a panel of animals will have been immunized and the spleen of animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).

Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.

One preferred murine myeloma cell is the NS-1 myeloma cell line (also termed P3-NS-1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.

Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion,

though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter *et al.* (1977). The use of
5 electrically induced fusion methods is also appropriate (Goding pp. 71-74, 1986).

Fusion procedures usually produce viable hybrids at low frequencies, about 1×10^{-6} to 1×10^{-8} . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally
10 continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is
15 supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine.

The preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key
20 enzymes of the salvage pathway, *e.g.*, hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.

This culturing provides a population of hybridomas from which specific hybridomas are
25 selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot
30 immunobinding assays, and the like.

The selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide MAbs. The cell lines may be exploited for MAb production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide MAbs in high concentration. The individual cell lines could also be cultured *in vitro*, where the MAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. MAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography.

The inventors also contemplate the use of a molecular cloning approach to generate monoclonals. For this, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning using cells expressing the antigen and control cells. The advantages of this approach over conventional hybridoma techniques are that approximately 10^4 times as many antibodies can be produced and screened in a single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

IV. ATTACHMENT OF CHELATORS TO MONOCLONAL ANTIBODIES

Methods for attachment of chelators to proteins, including monoclonal antibodies, are well known in the art. One of the earliest efforts at attachment of metal-binding groups to proteins was that of Gelewitz *et al.* (1954) who coupled azo-phenanthroline and azo-oxine to albumin; attempts were made to analyze the products by colorimetric titration with iron. Later, Sokolovsky *et al.*, (1967) converted lysozyme tyrosine to 3-aminotyrosine, and discussed the potential of this procedure to yield new heavy-atom derivatives for x-ray crystallography. Benisek and Richards (1968) explored the use of picolinimidate to produce metal-binding sites on proteins, with a similar goal.

The first chelate-protein conjugates that were stable enough for use *in vivo* were the protein azophenyl-EDTAs of Sundberg *et al.* (1974) which resulted from the initial ideas of Baldeschwieler [Meares *et al.* (1984)]. Those protein azophenyl-EDTA compounds were
5 studied over the years 1974-1979, during which the basic requirements of protein-chelate directed toward *in vivo* use were explored (Goodwin *et al.*, 1975; Meares *et al.*, 1976; Leung *et al.*, 1978; DeRiemer *et al.*, 1979).

In 1976, Krejcarek and Tucker activated DTPA by a mixed anhydride method and
10 coupled it to albumin (Krejcarek and Tucker, 1976). The product bound ^{111}In stably enough for many applications *in vivo*, and has been used by many nuclear medicine researchers since (Khaw *et al.*, 1980; Scheinberg, 1982). The procedure was subsequently improved by Hnatowich *et al.* (1983). Comparison of the stability of ^{111}In complexes in human serum under physiological conditions shows that the indium is lost from DTPA complexes much more rapidly than from
15 phenyl-EDTA complexes, whether bound to a protein or not (Yeh *et al.*, 1979). However, ^{111}In -DTPA complexes decompose slowly enough so that they are useful in many diagnostic procedures, including those involving antibodies.

By 1979, a general method for converting α -amino acids to bifunctional chelating agents
20 had been devised (Yeh *et al.*, 1979). This has permitted the synthesis of a wide range of structures from materials with an interesting choice of useful sidechains.

Typically, an amino acid such as L-phenylalanine is nitrated, esterified, and allowed to react with an amine RNH_2 . If $\text{R} = \text{H}$, the final product will be an EDTA analog, whereas if
25 $\text{R} = \text{H}_2\text{NCH}_2\text{CH}_2-$, the final product will be a DTPA analog. The amide is reduced, and the amines are carboxymethylated to form a chelating group, and then the aromatic nitro group is reduced to an amine. This aromatic amine can be further modified in several ways to form useful derivatives. For example, treatment with nitric acid renders a diazonium compound which may react with several different amino acid residues.

As noted above, in embodiments of the invention where the chelator is operatively attached to a monoclonal antibody, it is contemplated that such attachment may be by either covalent or ionic bond. One example of such an attachment is the diazophenyl coupling described above, but any other means of chemically binding a chelator to a monoclonal antibody may be used.

V. ANTIFUNGAL AGENTS

Fungal infections and the drugs used to treat them have traditionally been divided into two classes: superficial and systemic. This distinction is becoming increasingly arbitrary, however, as some of the drugs previously used to treat only one class of infection or the other are now used in both cases, with the differences being ones of mode of administration and/or concentration of active ingredient. Also, some infections, for example superficial mycoses, may now be treated either systemically or topically.

The classes of drugs used currently to treat systemic fungal infections include the polyenes, the imidazoles and triazoles, griseofulvin, and flucytosine. The polyenes bind to ergosterols in fungal membranes, resulting in the formation of transmembrane channels which allow the escape of metabolites essential to maintaining the viability of the fungal cell. Polyenes are highly toxic. The imidazoles and triazoles are structurally related and share the same antifungal spectrum and mechanism of action, namely the inhibition of the fungal sterol 14- α -demethylase enzyme system. Griseofulvin was isolated from a species of *Penicillium* and acts by inhibiting fungal mitosis. Flucytosine is a fluorinated pyrimidine which acts upon fungi by inhibiting thymidylate synthetase.

In addition to the above well-known classes of antifungal agents, some compounds more traditionally thought of as antibacterial agents, for example minocycline (a tetracycline derivative), have been demonstrated to have a fungistatic or fungicidal effect on the surface of a venous catheter when administered in combination with a chelator, for example EDTA, and other compounds. See, for example, United States patent 5,362,754 by Raad *et al.*, or United States patent application S/N 08/317,309 by Raad *et al.*, both of which are herein incorporated by reference.

Antifungal agents particularly preferred in connection with the present invention include the polyenes, most preferably Amphotericin B and liposomal Amphotericin B. The inventors have demonstrated that Amphotericin B acts synergistically in concert with the chelator EDTA to inhibit species of *Aspergillus* and *Fusarium*. A drug combination is said to exhibit synergism when the combination achieves a desired effect one order of magnitude or greater than the analogous effect of the most potent individual constituent of the combination. For example, referring to **FIG. 5**, Amphotericin B at a concentration of 1 µg/mL and EDTA at a concentration of 1 mg/mL act synergistically to inhibit the growth of *Aspergillus fumigatus* by a margin of almost two orders of magnitude relative to EDTA acting alone. The same effect is observed when the concentration of EDTA is reduced to 0.1 mg/mL (**FIG. 6**). Likewise, Amphotericin B and EDTA inhibit *Aspergillus flavus* synergistically, whether EDTA is present at 1.0 mg/mL or 0.1 mg/mL (**FIG. 7** and **FIG. 8**). This synergism extends to inhibition of *Fusarium solani* as well, as seen in **FIG. 9**. **FIG. 10** and **FIG. 11** show the synergistic inhibitory effect of liposomal Amphotericin B and EDTA against *A. fumigatus* and *F. solani*.

The inventors have demonstrated, remarkably and for the first time, that the chelators and antifungal agents of the present invention act together in a synergistic fashion to inhibit fungal pathogens. It is contemplated that as a consequence of this synergism described above between the chelators and the antifungal agents of the present invention, decreased dosages of antifungal agent will be sufficient to induce a fungicidal effect in a patient with a fungal infection, relative to the dosage required when administering an antifungal agent alone. Advantageously, a decreased dosage of antifungal agent, when used in conjunction with the chelators of the present invention, will serve to minimize any undesirable side effects which antifungal agents may induce in patients to whom they are administered.

Table 2 provides a representative list of antifungal agents useful in conjunction with the present invention. The list provided in Table 2 is not meant to be exhaustive.

Table 2
Antifungal Agents

UK 109,496 (Voriconazole)	Terbinafine
SCH 56592	BF-796
ER30346	MTCH 24
UK 9746	BTG-137586
UK 9751	RMP-7/ Amphotericin B
T 8581	Omoconazole
Flutrimazole	Amphotericin B
Cilofungin LY121019	Nystatin
LY303366 (Echinocandin)	Natamycin
L-743872 (Pneumocandin)	Clotrimazole
Pradimicins (MNS 18184)	Miconazole
Benanomycin	Ketoconazole
Ambisome	Terconazole
ABLC	Econazole
Liposomal Amphotericin	Itraconazole
ABCD	Fluconazole
Liposomal Nystatin	Griseofulvin
Nikkomycin Z	Flucytosine

VI. PHARMACEUTICAL COMPOSITIONS AND ROUTES OF ADMINISTRATION

Pharmaceutical compositions of the instant invention comprise an effective amount of at least a chelator dissolved or dispersed in a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable buffer, solvent or diluent, or aqueous medium. Pharmaceutical compositions of the instant invention may also comprise an effective amount of a chelator and an antifungal agent dissolved or dispersed in a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable buffer, solvent or diluent, or aqueous medium. Additionally, pharmaceutical compositions of the instant invention may comprise an effective amount of a chelator operatively attached to a monoclonal antibody dissolved or dispersed in a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable buffer, solvent or diluent, or aqueous medium. Also, pharmaceutical compositions of the instant invention comprise an effective amount of a chelator operatively attached to a monoclonal antibody, as well as an antifungal agent, all dissolved or dispersed in a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable buffer, solvent or diluent, or aqueous medium. Such compositions also can be referred to as inocula.

The phrases "pharmaceutically acceptable" or "pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a human. As used herein the terms "pharmaceutically acceptable carrier" and "pharmaceutically acceptable buffer, solvent or diluent" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The therapeutic compositions of the present invention may include classic pharmaceutical preparations. Administration of therapeutic compositions according to the present invention will be *via* any common route so long as the target tissue is available *via* that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration

will be by orthotopic, intradermal subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients. For treatment of conditions of the lungs, the preferred route is aerosol delivery to the lung.

5

An effective amount of the therapeutic composition is determined based on the intended goal. The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the therapeutic composition calculated to produce the desired responses, discussed above, in association with its administration, *i.e.*, the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection desired.

10

Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of administration, the intended goal of treatment (alleviation of symptoms *versus* cure) and the potency, stability and toxicity of the particular therapeutic substance.

15

Additional formulations are suitable for oral administration. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders. When the route is topical, the form may be a cream, ointment, salve or spray.

20

25

As used herein the terms "contact", "contacted", and "contacting", are used to describe the process by which an effective amount of a pharmacological agent, *e.g.*, any of the compounds disclosed in the present invention, comes in direct juxtaposition with the target cell.

30

For methods of treating mammals, pharmaceutical compositions may be administered by a variety of techniques, such as parenteral, topical or oral administration. For example, the

compositions of the instant invention may also be formulated for parenteral administration, *e.g.*, formulated for injection *via* the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. The preparation of an aqueous composition that contains one of the inventive compounds as an active ingredient will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use in preparing solutions or suspensions upon the addition of a liquid prior to injection can also be employed; and the preparations can also be emulsified.

Solutions of the inventive compositions as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, *etc.* Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to well known parameters. Sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions may also be useful. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

The compositions of the instant invention may also be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed, *e.g.*, with any free amino groups present), which are formed with inorganic acids such as, for

example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with any free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and
5 the like.

The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for
10 example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
15 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the compounds of the present invention in the required amount in the appropriate solvent with various of the other ingredients
20 enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a
25 powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are
30 easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variations in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

VII. PREVENTION AND TREATMENT OF DISSEMINATED FUNGAL INFECTIONS

The pharmaceutical compositions of the invention will be provided to a patient having a fungal infection in an amount sufficient to exert a fungicidal or fungistatic effect upon fungi contacted by the composition. It will be understood with benefit of this disclosure that such dosages may vary considerably according to the patient, the infection presented by the patient, and the particular active ingredients comprising the pharmaceutical composition.

The antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500, 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

More preferably, the antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the
5 quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

10 Most preferably, the antifungal agents of the present invention may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the
15 quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9 and about 10 mg per kg per day, and including all fractional dosages therebetween.

The chelators of the present invention may be administered to a patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per
20 kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500,
25 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

More preferably the chelators of the present invention may be administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about
30 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the

quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

5

Most preferably the chelators of the present invention may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the
10 quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, and about 10 mg per kg per day, and including all fractional dosages therebetween.

The monoclonal antibodies operatively attached to chelators may be administered to a
15 patient in an amount ranging from about 0.001 milligrams per kilogram of body weight per day to about 1000 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.001, 0.002, 0.003, *etc.*; 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
20 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 100, 101, 102, 103, 104, *etc.*; 500, 501, 502, 503, *etc.*; 600, 700, 800, 900, and about 1000 mg per kg per day, and including all fractional dosages therebetween.

More preferably, the monoclonal antibodies operatively attached to chelators may be
25 administered to a patient in an amount ranging from about 0.01 milligrams per kilogram of body weight per day to about 100 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.01, 0.02, 0.03, *etc.*; 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9,
30 *etc.*; 3, 4, 5, 6, 7, 8, 9, 10, *etc.*; 12, 13, 14, *etc.*; 50, 51, 52, 53, 54, *etc.*; 60, 70, 80, 90, and about 100 mg per kg per day, and including all fractional dosages therebetween.

Most preferably, the monoclonal antibodies operatively attached to chelators may be administered to a patient in an amount ranging from about 0.1 milligrams per kilogram of body weight per day to about 10 mg per kg per day, including all intermediate dosages therebetween. It will be readily understood that "intermediate dosages", in these contexts, means any dosages between the quoted ranges, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, *etc.*; 3, 4, 5, 6, 7, 8, 9, and about 10 mg per kg per day, and including all fractional dosages therebetween.

The pharmaceutical compositions of the present invention may be administered by any known route, including parenterally and otherwise. This includes oral, nasal (*via* nasal spray or nasal inhaler), buccal, rectal, vaginal or topical administration. Administration may also be by orthotopic, intradermal subcutaneous, intramuscular, intraperitoneal or intravenous injection and/or infusion. Such compositions may be administered as pharmaceutically acceptable compositions that include pharmacologically acceptable carriers, buffers or other excipients. The phrase "pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a human. For treatment of conditions of the lungs, the preferred route is aerosol delivery to the lung *via* bronchoalveolar lavage or the like.

VIII. PACKAGING AND KITS

The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the linked antibody/chelator may be placed, and preferably, suitably aliquoted. Where a second or third antifungal agent, other chelator, or additional component is provided, the kit will also generally contain a second, third or other additional container into which this component may be placed. The kits of the present invention will also typically include a means for containing the antibody/chelator, antifungal agent, other chelator, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Synergy Study

The goal of this study was to determine if there is a synergistic effect between EDTA and Amphotericin B and EDTA and Ambisome respectively. The data collected are displayed in FIG. 5-11. These figures are discussed elsewhere in the Detailed Description section. The studies were conducted in a laboratory incubator at a constant temperature of 30°C.

The medium was a single lot of liquid RPMI 1640 medium (Whittaker Bioproducts, Inc., Walkersville, MD) supplemented with 0.3g of L-glutamine per liter and 0.165 M MOPS buffer (34.54 g/liter) and without sodium bicarbonate.

Test inocula contained approximately 1×10^3 to 1×10^4 conidia/mL. To induce conidium and sporangiophore formation, fungi were grown on sabouraud dextrose agar plates at 35°C for 5 to 7 days. Each fungus was then covered with approximately 2 mL sterile 0.85% saline water. The suspension was then harvested by gently probing the colonies with sterile glass rods. The resulting mixture of conidia or sporangiophores and hyphal fragments was withdrawn and filtered through a sterile 4×4 gauze to a sterile tube. The homogenous suspension was later mixed with a vortex mixer for 30 s and the densities of the suspension were read and adjusted to a range of 80 to 85% transmittance. Inoculum of 0.1 mL was delivered to each flask containing 20 mL of RPMI and drug dilution series. The final conidia concentration ranged from 1×10^3 to 1×10^4 conidia/mL. A control flask was maintained without any drugs. The flasks were incubated in a shaker at 30°C for 24 to 48 h. Glass beads were added to all flasks with visible fungal growth in an attempt to homogenize the solution and achieve even

distribution of conidia for culture. Cultures were done at 0, 4, 24, and 48 h on sabouraud dextrose agar plates and incubated at 35°C for 48 h.

Amphotericin B for injection, USP (Gensia Laboratories, LTD.) was suspended and
5 diluted in sterile water and stored at 1 mg/mL in a glass vile in the dark at -70°C.

Ambisome was obtained in 50 mg vials and used immediately upon opening of the vial. Typically, 50 mg of Ambisome was diluted in 12 mL of sterile water. Further dilutions were performed as needed.

10

Edetate disodium INJ., USP (Abbott Laboratories, North Chicago, IL) was stored at a concentration of 150 mg/mL at 4°C.

Further dilutions were made to achieve the desired concentration of each drug at the time
15 of the study. For Amphotericin B and Ambisome, the concentration was 1.0 µg/mL and for EDTA the concentrations were 0.1 and 1.0 mg/mL.

EXAMPLE 2

Inhibition Study

20 The goal of this study was to determine if chelators have an inhibitory effect on species of *Aspergillus*, *Fusarium*, and *Candida*. The data collected are displayed in **FIGS. 1-4**. These figures are discussed elsewhere in the Detailed Description section. A spectrophotometer was used at a frequency of 660 nm to measure the absorbency of the solution.

25 For molds, all inocula were started at 1×10^4 conidia/mL. For yeast and bacteria, all inocula were started at 1×10^6 cfu/mL. The medium used was Mueller-Hinton.

The concentration of chelator in these studies was 0.35 mg EDTA per mL water.

EXAMPLE 3***In vivo* Prophetic Model**

In vivo studies will be conducted with either rabbits or mice, both of which are suitable animal models. Immunosuppression with cyclophosphamide should be given intravenously 3 days prior to commencement of the study in order to achieve neutropenia by the day of animal infection.

Treatment with all drugs begins 18 to 24 h after infection and continues for 10 days.

All animals surviving to day 11 are sacrificed. Their lungs, kidneys, liver, and spleen are removed and transferred into 5 mL of sterile saline, homogenized in a tissue grinder for 15 to 30 sec, and diluted to 10^{-1} , 10^{-2} , 10^{-3} , and 10^{-4} . A total of 1.0 mL of each dilution is spread onto a sabouraud dextrose agar plate and allowed to grow by incubating them at 37°C. The plates are then counted for quantitative analysis. Also, histopathology analysis will be conducted on all organs analyzed.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5

Benisek and Richards, *J. Biol. Chem.*, 243:4267, 1968.

Campbell, In: *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13, Burden and Von Knippenberg, (Eds.), Amsterdam, Elsevier, pp 75-83, 1984

10 DeRiemer, Meares, Goodwin, Diamanti, *J. Med. Chem.*, 22:019, 1979.

Gefter *et al.*, *Somatic Cell Genet.*, 3:231-236, 1977.

Gelewitz, Riedemann, Klotz, *Arch. Biochem. Biophys.*, 53:411, 1954.

Goding, 1986, In: *Monoclonal Antibodies: Principles and Practice*, 2nd ed., Academic Press, Orlando, FL, pp. 60-61, 65-66, 71-74, 1986.

15 Goodwin, Sundberg, Diamanti, Meares, In: *Radiopharmaceuticals*, Society of Nuclear Medicine, New York, p. 80, 1975.

Hnatowich, Layne, Childs, Lanteigne, Davis, Griffin, Doherty, *Science*, 220:613, 1983.

Khaw, Fallon, Strauss, Haber, *Science*, 209:295, 1980.

Kohler and Milstein, *Nature*, 256:495-497, 1975.

20 Krejcarek and Tucker, "Covalent attachment of chelating groups to macromolecules," *Biochem. Biophys. Res. Commun.*, 77:581-585, 1977.

Leung, Meares, Goodwin, *Int. J. Appl. Radiat. Isot.*, 29:687, 1978.

Meares, Goodwin, Leung, Girgis, Silvester, Nunn, Lavender, "Covalent attachment of metal chelates to proteins: The stability *in vivo* and *in vitro* of the conjugate of albumin with a

25 chelate of ¹¹¹indium," *Proc. Natl. Acad. Sci. U.S.A.*, 73:3803-3806, 1976.

Meares and Wensel, *Accts. Chem. Res.*, 17:202, 1984.

Sokolovsky, Riordan, Vallee, *Biochem. Biophys. Res. Commun.*, 27:20, 1967.

Sundberg, Meares, Goodwin, Diamanti, *Nature*, 250:587; *J. Med. Chem.*, 17:1304, 1974.

Yeh, Meares, Goodwin, *J. Radioanal. Chem.*, 53:327, 1979.

30 Yeh, Sherman, Meares, "A new route to "bifunctional" chelating agents: conversion of amino adds to analogs of ethylenedinitrilotetraacetic acid," *Anal. Biochem.*, 100:152-159, 1979.

United States patent 5,362,754 by Raad *et al.*

United States patent application S/N 08/317,309 by Raad *et al.*

CLAIMS:

1. A method of treating a systemic fungal infection comprising:
 - (a) obtaining a therapeutically effective amount of a pharmaceutical composition
5 comprising at least one chelator, at least one antifungal agent and a pharmaceutical excipient, diluent or adjuvant; and
 - (b) administering said pharmaceutical composition to a patient having a fungal infection.
- 10 2. The method of claim 1, wherein said chelator in said pharmaceutical composition may be selected from the group of chelators in Table 1.
3. The method of claim 2, wherein said chelator is EDTA.
- 15 4. The method of claim 1, wherein said antifungal agent may be selected from the group of antifungal agents in Table 2.
5. The method of claim 4, wherein said antifungal agent is Amphotericin B.
- 20 6. The method of claim 1, wherein said pharmaceutical composition comprises about 0.001 mg to about 1000 mg of chelator.
7. The method of claim 1, wherein said pharmaceutical composition comprises about 0.001 mg to about 1000 mg of antifungal agent.
- 25 8. The method of claim 1, wherein said pharmaceutical composition may be administered by injection, bronchoalveolar lavage, or by nasal drops, nasal spray, or nasal inhaler.
- 30 9. The method of claim 1, wherein said pharmaceutical composition may be administered by injection.

10. A pharmaceutical composition comprising at least one antifungal agent and at least one chelator.

11. The pharmaceutical composition of claim 10, wherein the chelator may be
5 selected from the group of chelators in Table 1.

12. The pharmaceutical composition of claim 10, wherein the antifungal agent may be selected from the group of antifungal agents in Table 2.

10 13. The pharmaceutical composition of claim 11, wherein the chelator is EDTA.

14. The pharmaceutical composition of claim 12, wherein the antifungal agent is Amphotericin B.

15 15. The pharmaceutical composition of claim 10, wherein the chelator is EDTA and the antifungal agent is Amphotericin B.

16. The pharmaceutical composition of claim 10, further defined as comprising about 0.001 mg to about 1000 mg of chelator.

20

17. The pharmaceutical composition of claim 10, further defined as comprising about 0.001 mg to about 1000 mg of antifungal agent.

18. The pharmaceutical composition of claim 10, further comprising at least one
25 monoclonal antibody specific for a targeted species of fungus.

19. The pharmaceutical composition of claim 10, wherein said monoclonal antibody is operatively attached to said chelator.

20. A pharmaceutical composition comprising at least one chelator, at least one antifungal agent and at least one monoclonal antibody, wherein said monoclonal antibody is operatively attached to said chelator.

5 21. The pharmaceutical composition of claim 20, wherein the chelator may be selected from the group of chelators in Table 1.

22. The pharmaceutical composition of claim 20, wherein the antifungal agent may be selected from the group of antifungal agents in Table 2.

10

23. The pharmaceutical composition of claim 21, wherein the chelator is EDTA.

24. The pharmaceutical composition of claim 22, wherein the antifungal agent is Amphotericin B.

15

25. The pharmaceutical composition of claim 20, wherein the chelator is EDTA and the antifungal agent is Amphotericin B.

26. The pharmaceutical composition of claim 20, further defined as comprising about
20 0.001 mg to about 1000 mg of chelator.

27. The pharmaceutical composition of claim 20, further defined as comprising about 0.001 mg to about 1000 mg of antifungal agent.

25 28. A method for treating a systemic fungal infection comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising at least one chelator, at least one antifungal agent and at least one monoclonal antibody, wherein said monoclonal antibody is operatively attached to said chelator.

1/11




FIG. 1

2/11




FIG. 2

3/11




FIG. 3

4/11




FIG. 4

5/11




FIG. 5

6/11




FIG. 6

7/11




FIG. 7

8/11




FIG. 8

9/11




FIG. 9

10/11




FIG. 10

11/11




FIG. 11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17564

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61K 31/70, 31/415, 31/135 US CL : 514/31, 33, 34, 393, 394, 401, 655 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/31, 33, 34, 393, 394, 401, 655 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, STN, CAS-ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,688,516 A (RAAD et al.) 18 November 1997, see the entire document.	1-28
X,P	US 5,696,164 A (SUN et al.) 09 December 1997, see the entire document.	1-28
X,P	US 5,780,049 A (DECKNER et al.) 14 July 1998, see the entire document.	1-28
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 21 NOVEMBER 1998		Date of mailing of the international search report 21 DEC 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Kevin E. Weddington</i> KEVIN E. WEDDINGTON Telephone No. (703) 308-1235